Prevention of T cell activation by interference of internalized intravenous immunoglobulin (IVIg) with MHC II-dependent native antigen presentation.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Clinical Immunology

• Publication date

  2011-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.clim.2011.06.009PMID 21824820
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mechanisms of Intravenous Immunoglobulin Action in the Treatment of Autoimmune Disorders

  2012cited by this paper
• Press Review

  2011cited by this paper
• Adenovirus 5 and chimeric adenovirus 5/F35 employ distinct B-lymphocyte intracellular trafficking routes that are independent of their cognate cell surface receptor.

  2010cited by this paper
• Indirect inhibition of in vivo and in vitro T-cell responses by intravenous immunoglobulins due to impaired antigen presentation.

  2010cited by this paper
• Inhibition of B cell-mediated antigen presentation by intravenous immunoglobulins (IVIg).

  2010cited by this paper
• Intravenous immunoglobulin therapy for autoimmune diseases

  2009cited by this paper
• Spontaneous internalization of IVIg in activated B cells.

  2009cited by this paper
• Activation of cryptic IgG reactive with BAFF, amyloid beta peptide and GM-CSF during the industrial fractionation of human plasma into therapeutic intravenous immunoglobulins.

  2009cited by this paper
• Anti-inflammatory actions of intravenous immunoglobulin.

  2008cited by this paper
• MHC class II molecules on the move for successful antigen presentation

  2008cited by this paper
• Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes".

  2008cited by this paper
• Exogenous CLIP localizes into endocytic compartment of cells upon internalization: implications for antigen presentation by MHC class II molecules.

  2008cited by this paper
• FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin.

  2007cited by this paper
• Intravenous Immunoglobulin: An Update on the Clinical Use and Mechanisms of Action

  2007cited by this paper
• FcγRIII-Dependent Inhibition of Interferon-γ Responses Mediates Suppressive Effects of Intravenous Immune Globulin

  2007cited by this paper
• Role of IVIg in autoimmune, neuroinflammatory and neurodegenerative disorders of the central nervous system: present and future prospects

  2006cited by this paper
• CD4 T Cells Play Major Effector Role and CD8 T Cells Initiating Role in Spontaneous Autoimmune Myocarditis of HLA-DQ8 Transgenic IAb Knockout Nonobese Diabetic Mice1

  2006cited by this paper
• Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology.

  2006cited by this paper
• Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells.

  2006cited by this paper
• Intravenous immunoglobulin ameliorates ITP via activating Fcγ receptors on dendritic cells

  2006cited by this paper
• Cell biology of antigen processing in vitro and in vivo.

  2005cited by this paper
• Th1 and Th2 lymphocytes in autoimmune disease.

  2005cited by this paper
• Therapeutic intravenous immunoglobulins.

  2005cited by this paper
• Pathogenic roles of B cells in human autoimmunity; insights from the clinic.

  2004cited by this paper
• The sympathetic nervous system is involved in variant Creutzfeldt-Jakob disease

  2003cited by this paper
• Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease.

  2003cited by this paper
• IVIg-mediated amelioration of murine ITP via FcgammaRIIB is independent of SHIP1, SHP-1, and Btk activity.

  2003cited by this paper
• Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin.

  2003cited by this paper
• Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases

  2003cited by this paper
• Intravenous immune globulins: an update for clinicians

  2003cited by this paper
• Antigen presentation and T cell stimulation by dendritic cells.

  2002cited by this paper
• Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor.

  2001cited by this paper
• In vivo activation of antigen-specific CD4 T cells.

  2001cited by this paper
• Development of type 1 diabetes despite severe hereditary B-cell deficiency.

  2001cited by this paper
• Presentation of antigens by MHC class II molecules: getting the most out of them.

  2001cited by this paper
• Autoimmune myocarditis does not require B cells for antigen presentation.

  1999cited by this paper
• Experimental autoimmune myasthenia gravis induction in B cell-deficient mice.

  1998cited by this paper
• The role of helper T cell subsets in autoimmune diseases.

  1998cited by this paper
• Capture and processing of exogenous antigens for presentation on MHC molecules.

  1997cited by this paper
• CD4+ T-cell subsets in autoimmunity.

  1997cited by this paper
• Production, specificity, and functionality of monoclonal antibodies to specific peptide-major histocompatibility complex class II complexes formed by processing of exogenous protein.

  1997cited by this paper
• Differential involvement of Th1 and Th2 cytokines in autoimmune diseases.

  1996cited by this paper
• Experimental Autoimmune Encephalomyelitis Induction in Genetically B Cell–deficient Mice

  1996cited by this paper
• Mechanisms of antigen uptake for presentation.

  1996cited by this paper
• The Th1/Th2 balance in autoimmunity.

  1995cited by this paper
• Interleukin 10 inhibits T cell alloreaction induced by human dendritic cells.

  1994cited by this paper
• Inhibition of Langerhans cell antigen-presenting function by IL-10. A role for IL-10 in induction of tolerance.

  1993cited by this paper
• Competition between foreign and self proteins in antigen presentation. Ovalbumin can inhibit activation of myelin basic protein-specific T cells.

  1990cited by this paper
• Inducible and constitutive MHC class II gene expression. Distinct tissue-specific genetic controls.

  1990cited by this paper
• Antigen recognition by H-2-restricted T cells. II. A tryptic ovalbumin peptide that substitutes for processed antigen.

  1984cited by this paper
• Identification of macrophage-like characteristics in a cultured murine tumor line.

  1975cited by this paper

• Role of HLA-I Structural Variants and the Polyreactive Antibodies They Generate in Immune Homeostasis

  2022cites this paper
• Natural Autoantibodies in Health and Disease

  2021cites this paper
• Fc Gamma Receptors and Their Role in Antigen Uptake, Presentation, and T Cell Activation

  2020cites this paper
• Acute kidney injury due to sucrose-containing intravenous immunoglobulins

  2019cites this paper
• Modulatory effect of intravenous immunoglobulin on Th17/Treg cell balance in women with unexplained recurrent spontaneous abortion

  2018cites this paper
• Immune modulation of i.v. immunoglobulin in women with reproductive failure

  2018cites this paper
• Massive immune response against IVIg interferes with response against other antigens in mice: A new mode of action?

  2017cites this paper
• Tregitopes and impaired antigen presentation: Drivers of the immunomodulatory effects of IVIg?

  2017influential citation
• Intravenous IgG (IVIG) and subcutaneous IgG (SCIG) preparations have comparable inhibitory effect on T cell activation, which is not dependent on IgG sialylation, monocytes or B cells.

  2015cites this paper
• Immunorégulation de la réaction du greffon contre l'hôte (GvHD) dans un modèle murin xénogénique : le rôle des immunoglobulines intraveineuses (IVIG)

  2015cites this paper
• ABO desensitization affects cellular immunity and infection control after renal transplantation

  2015cites this paper
• Immunological evidence and regulatory potential for cell-penetrating antibodies in intravenous immunoglobulin

  2015cites this paper
• T-cell inhibitory capacity of hyperimmunoglobulins is influenced by the production process.

  2014cites this paper
• Persistent Immune Activation in CVID and the Role of IVIg in Its Suppression

  2014cites this paper
• Dendritic cells as targets or therapeutics in rheumatic autoimmune disease

  2014cites this paper
• Suppression of blastogenesis and proliferation of activated CD4+ T cells: intravenous immunoglobulin (IVIg) versus novel anti‐human leucocyte antigen (HLA)‐E monoclonal antibodies mimicking HLA‐I reactivity of IVIg

  2014cites this paper
• CMV management in lung transplant recipients

  2014cites this paper
• Dendritic cell immunoreceptor: a novel receptor for intravenous immunoglobulin mediates induction of regulatory T cells.

  2014cites this paper
• The anti-inflammatory properties of intravenous immunoglobulin in a murine model of allergic airway disease ; effects on the development of regulatory T-cells

  2013cites this paper
• IVIg-mediated inhibition of antigen presentation: predominant role of naturally occurring cationic IgG.

  2012cites this paper
• Mouse background and IVIG dosage are critical in establishing the role of inhibitory Fcγ receptor for the amelioration of experimental ITP.

  2012cites this paper
• [Intravenous immunoglobulin: immunomodulatory key of the immune system].

  2012cites this paper